

Tuberculosis profile: Republic of Korea

Population 2022: 52 million

Estimates of TB burden*, 2022

	Number	(Rate per 100 000 population)
Total TB incidence	20 000 (19 000-22 000)	39 (37-42)
HIV-positive TB incidence		
MDR/RR-TB incidence**	850 (760-940)	1.6 (1.5-1.8)
HIV-negative TB mortality	1 900 (1 800-2 000)	3.7 (3.5-3.9)
HIV-positive TB mortality	37 (17-65)	0.07 (0.03-0.12)

Estimated proportion of TB cases with MDR/RR-TB*, 2022

New cases	3% (2.9-3.2)
Previously treated cases	8.4% (7.8-9)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2022	94% (87-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2022	10% (9-11)

TB case notifications, 2022

Total new and relapse	19 128
- % tested with rapid diagnostics at time of diagnosis	57%
- % with known HIV status	
- % pulmonary	77%
- % bacteriologically confirmed ^	83%
- % children aged 0-14 years	<1%
- % women (aged ≥15 years)	39%
- % men (aged ≥15 years)	61%
Total cases notified	20 383

TB/HIV care in new and relapse TB patients, 2022

	Number	(%)
Patients with known HIV status who are HIV-positive		
- on antiretroviral therapy		

Drug-resistant TB care**, 2022

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	100%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	100%
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	491
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	491
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	69
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	69
MDR/RR-TB cases tested for resistance to any fluoroquinolone	486

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2021	80%	20 542
Previously treated cases, excluding relapse, registered in 2021	77%	1 330
HIV-positive TB cases registered in 2021		
MDR/RR-TB cases started on second-line treatment in 2020	78%	460
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2020		

TB preventive treatment, 2022

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of household contacts of bacteriologically-confirmed TB cases on preventive treatment	14% (14-15)

* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.


** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone

^ Calculated for pulmonary cases only


^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2022 and patients who were not laboratory-confirmed


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)



HIV-negative TB mortality (Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2022 (Number)



Cases attributable to five risk factors, 2022 (Number)

